文献速递临床试验与 GCP基础与转化研究

亮氨酸与ACE抑制剂治疗肌少症(LACE试验):随机对照试验研究方案

Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2018-01-04

LACE是一项多中心、设盲、安慰剂对照的2×2析因随机试验,评估亮氨酸和培哚普利对肌少症患者的疗效。计划从英国招募440例70岁及以上肌少症患者,主要临床结局为基线与12个月间组间简易体能状况量表(SPPB)评分差异。

要点

  • 多中心、设盲、安慰剂对照2×2析因随机试验,评估亮氨酸和培哚普利对肌少症的疗效。
  • 计划招募440例70岁及以上、符合欧洲肌少症工作组定义的肌少症患者。
  • 主要临床结局为基线与12个月间组间SPPB评分差异,疗程共12个月。

核心结论

  • 该试验将首次对亮氨酸和培哚普利这两种新疗法在老年肌少症患者中的总体临床和成本效果进行稳健检验。

研究设计与样本

  • 多中心、设盲、安慰剂对照的2×2析因随机试验,评估亮氨酸和培哚普利(ACEi)在肌少症患者中的疗效。
  • 计划从英国初级和二级医疗服务机构招募440例患者。
  • 纳入标准为70岁及以上、符合欧洲肌少症工作组定义的肌少症(基于生物电阻抗分析示总骨骼肌量低,且步速低或握力低)的男性和女性患者。
  • 排除标准为存在ACEi、血管紧张素受体阻滞剂或亮氨酸禁忌证或已在服用者。
  • 参与者、临床团队、结局评估者和试验分析者均对治疗分配设盲。

关键数值与推荐

  • 主要临床结局为基线与12个月之间所有时间点简易体能状况量表(SPPB)评分的组间差异。
  • 次要结局包括双能X线吸收法测定的四肢肌肉量、肌肉力量、日常生活活动、生活质量、计步器步数活动和跌倒。
  • 参与者接受培哚普利或安慰剂、亮氨酸或安慰剂,总疗程12个月。
  • 将检测包括microRNA、神经激素、基因多态性和炎症标志物在内的生物标志物面板,以探索应答预测因素并进一步阐明肌少症机制。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with sarcopenia. METHODS: Leucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 × 2 factorial randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia (based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength) will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of either perindopril or placebo and either leucine or placebo. DISCUSSION: The results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies for older patients with sarcopenia. TRIAL REGISTRATION: ISRCTN, ISRCTN90094835 . Registered on 18 February 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Band MM, Sumukadas D, Struthers AD, et al. Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. Trials. 2018. PMID: 29301558. doi:10.1186/s13063-017-2390-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。